Menarini shares new analysis from EMERALD clinical study of Orserdu
Privately-held Italian drugmaker Menarini has announced results from a new analysis of the pivotal EMERALD clinical study that suggest that oral single-agent Orserdu (elacestrant) may be effective in ER+, HER2- advanced or metastatic breast cancer patients with non-detected ESR1-mut whose disease has progressed within six months of treatment with a CDK4/6i. Menarini’s wholly-owned subsidiary Stemline … [Read more…]